{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:43:47Z","timestamp":1794411827453,"version":"4.9.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To examine the characteristics of blood lymphocyte subsets in dermatomyositis-interstitial lung disease (DM-ILD) inflicted patients with positive anti-melanoma differentiation-associated gene 5 (anti-MDA5), as well as its prognosis value in this set of patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data were retrospectively collected from 253 DM-ILD patients from three hospitals in China between January 2016 to January 2021. Patients were grouped into anti-MDA5 antibody positive group (MDA5<jats:sup>+<\/jats:sup> DM-ILD) and anti-MDA5 antibody negative group (MDA5<jats:sup>\u2212<\/jats:sup> DM-ILD) based on myositis-specific autoantibody test results. Demographic characteristics, lymphocyte subsets patterns and other clinical features were compared between the two groups. The association of lymphocyte subsets with 180-day mortality was investigated using survival analysis in MDA5<jats:sup>+<\/jats:sup> DM-ILD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Out of 253 eligible patients with DM-ILD, 59 patients were anti-MDA5<jats:sup>+<\/jats:sup> and 194 were anti-MDA5<jats:sup>\u2212<\/jats:sup>. Peripheral blood lymphocyte count, CD3<jats:sup>+<\/jats:sup> count, percentage of CD3<jats:sup>+<\/jats:sup>, CD3<jats:sup>+<\/jats:sup>CD4<jats:sup>+<\/jats:sup> count, and CD3<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup> count was lower in MDA5<jats:sup>+<\/jats:sup> DM-ILD than in MDA5<jats:sup>\u2212<\/jats:sup> DM-ILD<jats:sup>\u2212<\/jats:sup> (all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) as well as CD3<jats:sup>\u2212<\/jats:sup>CD19<jats:sup>+<\/jats:sup> count (<jats:italic>P<\/jats:italic>\u2009=\u20090.04). In MDA5<jats:sup>+<\/jats:sup> DM-ILD, CD3<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup> count\u2009\u2264\u200949.22 cell\/\u03bcL (HR\u2009=\u20093.81, 95%CI [1.20,12.14]) and CD3-CD19<jats:sup>+<\/jats:sup> count\u2009\u2264\u2009137.64 cell\/\u03bcL (HR\u2009=\u20093.43, 95%CI [1.15,10.24]) were independent predictors of mortality. CD3<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup> count\u2009\u2264\u200931.38 cell\/\u03bcL was associated with a higher mortality risk in all DM-ILD patients (HR\u2009=\u20098.6, 95%CI [2.12,31.44]) after adjusting for anti-MDA5 and other clinical characteristics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Significant lymphocytes decrease was observed in MDA5<jats:sup>+<\/jats:sup> DM-ILD patients. CD3<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup> cell count was associated with worse prognosis in both MDA5<jats:sup>+<\/jats:sup> DM-ILD and all DM-ILD patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-023-02706-y","type":"journal-article","created":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T06:02:29Z","timestamp":1698472949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Characteristics and prognostic implications of peripheral blood lymphocyte subsets in patients with anti-MDA5 antibody positive dermatomyositis-interstitial lung disease"],"prefix":"10.1186","volume":"23","author":[{"given":"Fang-Ping","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Shan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Ying","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ling","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Wei","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Wen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Lei","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yu","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Hui","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,28]]},"reference":[{"issue":"1","key":"2706_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13075-017-1506-7","volume":"20","author":"Y Sugiyama","year":"2018","unstructured":"Sugiyama Y, Yoshimi R, Tamura M, et al. The predictive prognostic factors for polymyositis\/dermatomyositis-associated interstitial lung disease. Arthritis Res Ther. 2018;20(1):7.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2706_CR2","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12890-023-02542-0","volume":"23","author":"H Zhang","year":"2023","unstructured":"Zhang H, Yue J, Hou X, et al. Rapidly progressive interstitial lung disease combined with pneumocystis jiroveci pneumonia in a patient with single anti-TIF-1\u03b3 antibody positive dermatomyositis in the context of an underlying tumor. BMC Pulm Med. 2023;23(1):248.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"2706_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/joim.12451","volume":"280","author":"Z Betteridge","year":"2016","unstructured":"Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med. 2016;280(1):8\u201323.","journal-title":"J Intern Med"},{"issue":"4","key":"2706_CR4","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1136\/annrheumdis-2017-212149","volume":"77","author":"Y Kochi","year":"2018","unstructured":"Kochi Y, Kamatani Y, Kondo Y, et al. Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Ann Rheum Dis. 2018;77(4):602\u201311.","journal-title":"Ann Rheum Dis"},{"key":"2706_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/OARRR.S231195","volume":"12","author":"FM Alenzi","year":"2020","unstructured":"Alenzi FM. Myositis Specific Autoantibodies: A Clinical Perspective. Open Access Rheumatol. 2020;12:9\u201314.","journal-title":"Open Access Rheumatol"},{"issue":"11","key":"2706_CR6","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1007\/s10067-022-06291-z","volume":"41","author":"L Wen","year":"2022","unstructured":"Wen L, Chen X, Cheng Q, et al. Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies: results from a cohort from China. Clin Rheumatol. 2022;41(11):3419\u201327.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"2706_CR7","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1684\/ejd.2019.3634","volume":"29","author":"SI Motegi","year":"2019","unstructured":"Motegi SI, Sekiguchi A, Toki S, et al. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease. Eur J Dermatol. 2019;29(5):511\u20137.","journal-title":"Eur J Dermatol"},{"issue":"1","key":"2706_CR8","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1212\/WNL.0000000000009727","volume":"95","author":"Y Allenbach","year":"2020","unstructured":"Allenbach Y, Uzunhan Y, Toquet S, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases. Neurology. 2020;95(1):e70\u20138.","journal-title":"Neurology"},{"issue":"2","key":"2706_CR9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12016-020-08822-5","volume":"60","author":"W Wu","year":"2021","unstructured":"Wu W, Guo L, Fu Y, et al. Interstitial lung disease in Anti-MDA5 positive dermatomyositis. Clin Rev Allergy Immunol. 2021;60(2):293\u2013304.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"2706_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3899\/jrheum.160682","volume":"44","author":"S Moghadam-Kia","year":"2017","unstructured":"Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Antimelanoma differentiation-associated Gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis. J Rheumatol. 2017;44(3):319\u201325.","journal-title":"J Rheumatol"},{"issue":"20","key":"2706_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015578","volume":"98","author":"J Temmoku","year":"2019","unstructured":"Temmoku J, Sato S, Fujita Y, et al. Clinical significance of myositis-specific autoantibody profiles in Japanese patients with polymyositis\/dermatomyositis. Medicine (Baltimore). 2019;98(20): e15578.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"2706_CR12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","volume":"82","author":"ME DeWane","year":"2020","unstructured":"DeWane ME, Waldman R, Lu J. Dermatomyositis: Clinical features and pathogenesis. J Am Acad Dermatol. 2020;82(2):267\u201381.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2706_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12016-016-8527-x","volume":"52","author":"A Ceribelli","year":"2017","unstructured":"Ceribelli A, De Santis M, Isailovic N, Gershwin ME, Selmi C. The immune response and the pathogenesis of idiopathic inflammatory myositis: a critical review. Clin Rev Allergy Immunol. 2017;52(1):58\u201370.","journal-title":"Clin Rev Allergy Immunol"},{"key":"2706_CR14","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3389\/fmed.2019.00326","volume":"6","author":"B Hervier","year":"2019","unstructured":"Hervier B, Uzunhan Y. Inflammatory myopathy-related interstitial lung disease: from pathophysiology to treatment. Front Med (Lausanne). 2019;6:326.","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"2706_CR15","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.jid.2019.10.020","volume":"140","author":"C Cassius","year":"2020","unstructured":"Cassius C, Amode R, Delord M, et al. MDA5(+) dermatomyositis is associated with stronger skin type I interferon transcriptomic signature with upregulation of IFN-\u03ba transcript. J Invest Dermatol. 2020;140(6):1276-1279.e7.","journal-title":"J Invest Dermatol"},{"issue":"12","key":"2706_CR16","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1093\/rheumatology\/keaa266","volume":"59","author":"W Huang","year":"2020","unstructured":"Huang W, Ren F, Luo L, et al. The characteristics of lymphocytes in patients positive for anti-MDA5 antibodies in interstitial lung disease. Rheumatology (Oxford). 2020;59(12):3886\u201391.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"2706_CR17","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1007\/s00296-011-2323-y","volume":"32","author":"F Chen","year":"2012","unstructured":"Chen F, Wang D, Shu X, Nakashima R, Wang G. Anti-MDA5 antibody is associated with A\/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatol Int. 2012;32(12):3909\u201315.","journal-title":"Rheumatol Int"},{"key":"2706_CR18","doi-asserted-by":"publisher","first-page":"27479","DOI":"10.1038\/srep27479","volume":"6","author":"W Li","year":"2016","unstructured":"Li W, Tian X, Lu X, et al. Significant decrease in peripheral regulatory B cells is an immunopathogenic feature of dermatomyositis. Sci Rep. 2016;6:27479.","journal-title":"Sci Rep"},{"issue":"4","key":"2706_CR19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40674-021-00186-x","volume":"7","author":"A Selva-O'Callaghan","year":"2021","unstructured":"Selva-O\u2019Callaghan A, Romero-Bueno F, Trallero-Aragu\u00e1s E, et al. Pharmacologic treatment of Anti-MDA5 rapidly progressive interstitial lung disease. Curr Treatm Opt Rheumatol. 2021;7(4):319\u201333.","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"2706_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.105983","volume":"172","author":"MM Mao","year":"2020","unstructured":"Mao MM, Xia S, Guo BP, et al. Ultra-low dose rituximab as add-on therapy in anti-MDA5-positive patients with polymyositis \/dermatomyositis associated ILD. Respir Med. 2020;172: 105983.","journal-title":"Respir Med"},{"issue":"6","key":"2706_CR21","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1007\/s10067-020-05530-5","volume":"40","author":"Y Ge","year":"2021","unstructured":"Ge Y, Li S, Tian X, He L, Lu X, Wang G. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy. Clin Rheumatol. 2021;40(6):2311\u20137.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"2706_CR22","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344\u20137.","journal-title":"N Engl J Med"},{"issue":"8","key":"2706_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403\u20137.","journal-title":"N Engl J Med"},{"issue":"6","key":"2706_CR24","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/00002281-199911000-00005","volume":"11","author":"RD Sontheimer","year":"1999","unstructured":"Sontheimer RD. Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis. Curr Opin Rheumatol. 1999;11(6):475\u201382.","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"2706_CR25","doi-asserted-by":"publisher","first-page":"523","DOI":"10.4103\/lungindia.lungindia_4_18","volume":"35","author":"A Chawla","year":"2018","unstructured":"Chawla A, Kumar T, Mukherjee P. Antisynthetase syndrome: Initial and follow-up imaging features. Lung India. 2018;35(6):523\u20135.","journal-title":"Lung India"},{"issue":"4","key":"2706_CR26","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.chest.2020.04.057","volume":"158","author":"X Lian","year":"2020","unstructured":"Lian X, Zou J, Guo Q, et al. Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: the FLAIR model. Chest. 2020;158(4):1535\u201345.","journal-title":"Chest"},{"key":"2706_CR27","doi-asserted-by":"publisher","first-page":"2024869","DOI":"10.1155\/2020\/2024869","volume":"2020","author":"Y Li","year":"2020","unstructured":"Li Y, Li Y, Wu J, et al. Predictors of poor outcome of Anti-MDA5-Associated rapidly progressive interstitial lung disease in a Chinese cohort with dermatomyositis. J Immunol Res. 2020;2020:2024869.","journal-title":"J Immunol Res"},{"issue":"12","key":"2706_CR28","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s10067-012-2075-4","volume":"31","author":"DX Wang","year":"2012","unstructured":"Wang DX, Lu X, Zu N, et al. Clinical significance of peripheral blood lymphocyte subsets in patients with polymyositis and dermatomyositis. Clin Rheumatol. 2012;31(12):1691\u20137.","journal-title":"Clin Rheumatol"},{"key":"2706_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105912","volume":"77","author":"M Feng","year":"2019","unstructured":"Feng M, Guo H, Zhang C, et al. Absolute reduction of regulatory T cells and regulatory effect of short-term and low-dose IL-2 in polymyositis or dermatomyositis. Int Immunopharmacol. 2019;77: 105912.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"2706_CR30","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3892\/mmr.2017.6693","volume":"16","author":"X Shu","year":"2017","unstructured":"Shu X, Chen F, Peng Q, et al. Potential role of autophagy in T-cell survival in polymyositis and dermatomyositis. Mol Med Rep. 2017;16(2):1180\u20138.","journal-title":"Mol Med Rep"},{"issue":"1","key":"2706_CR31","doi-asserted-by":"publisher","first-page":"6458","DOI":"10.1038\/s41467-022-34145-4","volume":"13","author":"Y Ye","year":"2022","unstructured":"Ye Y, Chen Z, Jiang S, et al. Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications. Nat Commun. 2022;13(1):6458.","journal-title":"Nat Commun"},{"issue":"5","key":"2706_CR32","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1378\/chest.08-2740","volume":"136","author":"H Mukae","year":"2009","unstructured":"Mukae H, Ishimoto H, Sakamoto N, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest. 2009;136(5):1341\u20137.","journal-title":"Chest"},{"issue":"1","key":"2706_CR33","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/art.41075","volume":"72","author":"AS Galindo-Feria","year":"2020","unstructured":"Galindo-Feria AS, Albrecht I, Fernandes-Cerqueira C, et al. Proinflammatory Histidyl-Transfer RNA Synthetase-Specific CD4+ T Cells in the Blood and Lungs of Patients With Idiopathic Inflammatory Myopathies. Arthritis Rheumatol. 2020;72(1):179\u201391.","journal-title":"Arthritis Rheumatol"},{"key":"2706_CR34","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jneuroim.2019.04.014","volume":"332","author":"G Dzangu\u00e9-Tchoupou","year":"2019","unstructured":"Dzangu\u00e9-Tchoupou G, Allenbach Y, Preu\u00dfe C, Stenzel W, Benveniste O. Mass cytometry reveals an impairment of B cell homeostasis in anti-synthetase syndrome. J Neuroimmunol. 2019;332:212\u20135.","journal-title":"J Neuroimmunol"},{"issue":"3","key":"2706_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00296-001-0146-y","volume":"21","author":"I Yamadori","year":"2001","unstructured":"Yamadori I, Fujita J, Kajitani H, et al. Lymphocyte subsets in lung tissues of interstitial pneumonia associated with untreated polymyositis\/dermatomyositis. Rheumatol Int. 2001;21(3):89\u201393.","journal-title":"Rheumatol Int"},{"issue":"7","key":"2706_CR36","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/1348-0421.12265","volume":"59","author":"DE Noyola","year":"2015","unstructured":"Noyola DE, Ju\u00e1rez-Vega G, Monjar\u00e1s-\u00c1vila C, et al. NK cell immunophenotypic and genotypic analysis of infants with severe respiratory syncytial virus infection. Microbiol Immunol. 2015;59(7):389\u201397.","journal-title":"Microbiol Immunol"},{"key":"2706_CR37","doi-asserted-by":"crossref","unstructured":"Pawlitzki M, Nelke C, Rolfes L, et al. NK Cell patterns in idiopathic inflammatory myopathies with pulmonary affection. Cells. 2021;10(10):2551.","DOI":"10.3390\/cells10102551"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02706-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-023-02706-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02706-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T06:04:10Z","timestamp":1698473050000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-023-02706-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,28]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2706"],"URL":"https:\/\/doi.org\/10.1186\/s12890-023-02706-y","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,28]]},"assertion":[{"value":"19 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of Chao-Yang Hospital, Capital Medical University (Project ID 2023-4-10-3), which waived the need for written informed consent because of the retrospective study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"411"}}